Acusphere (OTCPK:ACUS) - Stock Price, News & Analysis

ACUS Stock Overview

Operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. More details

ACUS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($4)

Latest financial reports are more than a year old

Shares are highly illiquid

Acusphere, Inc. Competitors

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

MJ Holdings

OTCPK:MJNE

US$58.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Price History & Performance

Summary of all time highs, changes and price drops for Acusphere
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
33 Year Change	-99.00%
5 Year Change	-100.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ACUS	US Pharmaceuticals	US Market
7D	0%	4.2%	2.0%
1Y	0%	13.7%	32.4%

Return vs Industry: ACUS underperformed the US Pharmaceuticals industry which returned 24.3% over the past year.

Return vs Market: ACUS underperformed the US Market which returned 40.3% over the past year.

Price Volatility

Is ACUS's price volatile compared to industry and market?
ACUS volatility
ACUS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ACUS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ACUS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	n/a	n/a	www.acusphere.com

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension.

Acusphere, Inc. Fundamentals Summary

How do Acusphere's earnings and revenue compare to its market cap?
ACUS fundamental statistics
Market cap	US$4.00
Earnings (TTM)	-US$69.42m
Revenue (TTM)	US$2.68m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ACUS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACUS income statement (TTM)
Revenue	US$2.68m
Cost of Revenue	US$34.45m
Gross Profit	-US$31.77m
Other Expenses	US$37.65m
Earnings	-US$69.42m

Last Reported Earnings

Dec 31, 2008

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ACUS perform over the long term?

See historical performance and comparison